Maria Grammenou-Pomoni

Maria Grammenou-Pomoni

Auto-generated profile, based on publicly available information

Maria Grammenou-Pomoni

Imaging and Research Unit, University of Athens, Athens, Greece

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2013 in CardioVascular and Interventional Radiology
Verified
Journal Article
Open access
PDF file
KMKATERINA MALAGARI
KATERINA MALAGARI
MPMaria Pomoni
Maria Pomoni
HMHippocrates Moschouris
Hippocrates Moschouris
Alexis  KelekisAlexis Kelekis
Alexis Kelekis
ACAngelos Charokopakis
Angelos Charokopakis
DKDimitrios A. Kelekis
Dimitrios A. Kelekis
Background This study examined the safety, pharmacokinetics, and efficacy of transarterial chemoembolization of hepatocellular carcinoma (HCC) using a newly developed size of a superabsorbent polymer drug-eluting embolic material. Methods Forty-five patients with documented HCC (Child–Pugh score A/B: 55.5 %/44.5 %) were embolized with HepaSphere microspheres 30–60 μm with escalation of lesion, dose, and frequency of re-embolization. Local response was evaluated with modified response evaluation criteria in solid tumors (mRECIST). Plasma levels of doxorubicin were measured in 24 patients at baseline and at 5, 20, 40, 60, and 120 min, at 6, 24, and 48 h, and at 7 days, respectively, to determine doxorubicin in plasma (Cmax) and area under the curve (AUC). Measurements of three patients who underwent lipiodol-based conventional chemoembolization (c-TACE) were also performed. Results TACE with HepaSphere was well tolerated with an acceptable safety profile and no 30-day mortality. Response rates were calculated on intention-to-treat basis with complete response (CR) in 17.8 % reaching 22.2 % for the target lesion. Overall partial response (PR) was seen in 51.1 %, stable disease in 20 %, and progressive disease in 11.1 % of patients. Overall objective response (CR + PR), including patients treated at all dosages of doxorubicin, was seen in 68.9 % of cases. After a median follow-up of 15.6 months, 1-year survival is 100 %. Doxorubicin AUC was significantly lower in patients with HepaSphere 30–60 μm (35,195 ± 27,873 ng × min/ml) than in patients with conventional TACE (103,960 ± 16,652 ng × min/ml; p = 0.009). Cmax was also significantly lower with HepaSphere 30–60 μm (83.9 ± 32.1 ng/ml) compared with c-TACE (761.3 ± 58.8 ng/ml; p = 0.002). Conclusion HepaSphere 30–60 μm is an effective drug-eluting embolic material with a favourable pharmacokinetic profile.

12 January 2010 in Skeletal Radiology
Verified
Journal Article
Closed access
PDF file
SMSophia Mylona
Sophia Mylona
SPSofia Patsoura
Sofia Patsoura
PGPanagiota Galani
Panagiota Galani
GKGeorgios Karapostolakis
Georgios Karapostolakis
APAnastasia Pomoni
Anastasia Pomoni
LTLoukas Thanos
Loukas Thanos

24 June 2008 in CardioVascular and Interventional Radiology
Verified
Journal Article
Closed access
PDF file
EBElias N. Brountzos
Elias N. Brountzos
NPNikolaos Ptohis
Nikolaos Ptohis
MGMaria Grammenou-Pomoni
Maria Grammenou-Pomoni
IPIrini Panagiotou
Irini Panagiotou
DKDimitrios Kelekis
Dimitrios Kelekis
NKNikolaos Kelekis
Nikolaos Kelekis